Pfizer dofetilide reduces CHF hospitalization by 25% in DIAMOND study; mortality effect "neutral".

PFIZER DOFETILIDE DIAMOND STUDY SHOWS 25% REDUCTION IN CHF HOSPITALIZATION and no difference from placebo in the primary endpoint of all-cause mortality, study investigator Mogens Moller, MD, Odense University Hospital (Denmark), reported Aug. 26 at the European Society of Cardiology in Stockholm. Pfizer expects to file an NDA for the class III anti-arrhythmic drug in early 1998. Xelide has been mentioned as a potential brand name for dofetilide.